tebnow← All categories
Category

Clinical Research

610 articles indexed

Reassessing R-CHOP Efficacy in High-Risk Large B-Cell Lymphoma Treatment

Patients with high-risk large B-cell lymphoma (LBCL), characterized by an International Prognostic Index (IPI) score of 3–5, continue to face poor treatment outcomes. R-CHOP, the standard first-line therapy for over 20 years, achieves durable remissions in about 60% of cases. However, despite advancements in understanding LBCL's biology and molecular diversity, efforts to enhance treatment efficacy—such as intensifying chemotherapy, utilizing alternative anti-CD20 antibodies, and incorporating targeted therapies—have largely failed to yield significant improvements in survival rates. This ongoing challenge highlights the need for innovative approaches to treatment, particularly for high-risk patients who are in urgent need of more effective therapeutic options. As research continues, the medical community is urged to explore new strategies that could potentially transform the management of LBCL and improve patient outcomes.

The Lancet/1d ago

large B-cell lymphoma / R-CHOP / oncology / treatment outcomes / chemotherapy

Tafasitamab and Lenalidomide Show Promise in High-Risk DLBCL, but Safety Concerns Arise

A recent phase 3 trial, frontMIND, evaluated the efficacy and safety of tafasitamab combined with lenalidomide and R-CHOP compared to R-CHOP alone in patients with high-risk diffuse large B-cell lymphoma (DLBCL). The results indicated a significant improvement in progression-free survival for the combination therapy, suggesting a potential new standard for first-line treatment in this patient population. However, the study also revealed an increased incidence of adverse events, including treatment-emergent adverse events that led to fatalities, raising concerns about the safety profile of the combination therapy. While overall survival data remains immature and follow-up is ongoing, the findings underscore the need for careful monitoring of patients receiving tafasitamab and lenalidomide. The trial's design included a global, randomized, double-blind, placebo-controlled approach, enhancing the reliability of the results. Further analyses, particularly focusing on circulating tumor DNA, are anticipated to provide insights into whether deeper molecular responses are contributing to the observed benefits in progression-free survival. This trial is particularly relevant for oncologists and healthcare professionals involved in the treatment of DLBCL, as it may influence future treatment protocols. The ongoing follow-up and additional analyses will be crucial in determining the long-term implications of these findings and the overall viability of tafasitamab and lenalidomide in clinical practice.

The Lancet · 1d ago

New Trials of ADCs in NSCLC Show No Survival Benefit, Sparking Interest in Combination Therapies

Recent phase 3 trials assessing the efficacy of TROP2 antibody-drug conjugates (ADCs) datopotamab deruxtecan and sacituzumab govitecan in treating non-small-cell lung cancer (NSCLC) have yielded disappointing results, revealing no significant survival advantage over the standard second-line treatment, docetaxel. These findings are crucial as they challenge the initial optimism surrounding ADCs as a first-line treatment option for NSCLC, a disease that remains a leading cause of cancer-related mortality worldwide. Despite the lack of survival benefit demonstrated in these trials, the unique mechanism of action of ADCs, particularly their ability to modulate the tumor microenvironment, has generated renewed interest among researchers and clinicians. This has led to discussions about the potential for combining ADCs with immune checkpoint inhibitors (ICIs), which have revolutionized cancer treatment by enhancing the immune system's ability to target and destroy cancer cells. The implications of these findings are significant for healthcare professionals involved in oncology, as they highlight the need for continued exploration of combination therapies that may improve patient outcomes. As the landscape of NSCLC treatment evolves, understanding the interplay between ADCs and ICIs could lead to more effective strategies for managing this challenging disease. Moving forward, further research is necessary to explore the optimal combinations and sequencing of these therapies, as well as to identify patient populations that may benefit most from such approaches. The ongoing investigation into ADCs and their role in NSCLC treatment will be critical in redefining first-line standards and improving survival rates for patients with this aggressive cancer.

The Lancet · 2d ago

Dapirolizumab Pegol Shows Promise as a New Treatment for Systemic Lupus Erythematosus

Dapirolizumab pegol, a monoclonal antibody targeting CD40, is emerging as a potential new treatment for systemic lupus erythematosus (SLE), an autoimmune disease that predominantly affects women and typically manifests in the third or fourth decade of life. SLE is characterized by a range of clinical symptoms and the presence of autoantibodies, including anti-nuclear antibodies and anti-double-stranded DNA. The disease can exhibit persistent low-grade activity with intermittent flares, or patients may experience symptom-free periods or prolonged quiescence. The introduction of dapirolizumab pegol could provide a novel therapeutic option for managing SLE, addressing the unmet needs of patients who suffer from this complex condition. As research progresses, healthcare professionals will be closely monitoring the efficacy and safety of this treatment, which may significantly impact the management of SLE and improve patient outcomes.

The Lancet · 2d ago

Rimteravimab Shows Safety and Tolerability in Phase 1 Trials for Mild-to-Moderate COVID-19

Recent Phase 1 clinical trials have evaluated rimteravimab (XVR011), a novel heavy chain-only antibody, in both healthy adults and patients hospitalized with mild-to-moderate COVID-19. The trials aimed to assess the safety, tolerability, pharmacokinetics, and immunogenicity of this therapeutic candidate, which targets the receptor binding domain of the SARS-CoV-2 spike protein. In the first trial involving 30 healthy volunteers, no serious adverse events were reported, with 73.3% experiencing mild treatment-emergent adverse events (TEAEs), predominantly headaches. The second trial included 27 hospitalized patients, where 25.9% reported mild to moderate TEAEs, all of which resolved by the study's conclusion. Pharmacokinetic analysis revealed a dose-proportional increase in exposure, with a half-life ranging from 11.4 to 17.0 days across both studies. Notably, while some patients developed anti-drug antibodies (ADAs), this did not significantly affect the pharmacokinetics or pharmacodynamics of rimteravimab. The studies highlighted the potential of VHH-Fc constructs in treating COVID-19, although the second part of the Phase 1b study was halted due to the loss of rimteravimab's potency against the Omicron variant. These findings underscore the promising safety profile of rimteravimab, paving the way for further clinical development of heavy chain-only antibodies in the fight against COVID-19 and potentially other viral infections. Future studies will be essential to explore the efficacy of rimteravimab against emerging variants and to establish its role in therapeutic regimens for COVID-19.

PLOS Medicine · 2d ago

New Bundibugyo Virus Outbreak Declared in Ituri Province, DRC

On May 15, 2026, the Ministry of Public Health, Hygiene and Social Welfare of the Democratic Republic of the Congo announced a new outbreak of Bundibugyo virus disease in Ituri Province. This outbreak is significant as it marks the 17th Ebola virus disease outbreak in the country and the second instance of Bundibugyo virus disease since its first recognition in 2007-08 in Uganda. The affected health zones include Rwampara, Mongbwalu, and Bunia, raising concerns about the potential spread of the virus in these regions. Laboratory tests have confirmed the presence of the Bundibugyo virus (Orthoebolavirus bundibugyoense), which is known for its severe impact on public health. The previous Bundibugyo outbreaks in 2007-08 and 2012 resulted in significant morbidity and mortality, highlighting the need for immediate public health interventions. The current situation necessitates close monitoring and rapid response to contain the virus and prevent further transmission. Healthcare professionals and local authorities are urged to implement stringent surveillance and control measures to mitigate the outbreak's impact. The situation remains fluid, and ongoing assessments will be crucial in determining the next steps in managing this public health crisis.

The Lancet · 2d ago

Ebola Outbreak in DR Congo and Uganda Highlights Epidemic Preparedness Challenges

A new outbreak of Ebola virus disease, specifically caused by the Bundibugyo virus, has been declared in the Democratic Republic of Congo (DR Congo) and Uganda, raising significant concerns about the region's epidemic preparedness. As of May 15, 2026, there have been 246 suspected cases and 80 deaths reported in Ituri, DR Congo, including four fatalities among confirmed cases. The outbreak has also led to confirmed imported cases in Kampala, Uganda, prompting the World Health Organization (WHO) to declare a Public Health Emergency of International Concern. The situation is particularly alarming due to the high case fatality rates associated with previous outbreaks, which have ranged from 30% to 50%. The current outbreak has already demonstrated concerning levels of transmission among healthcare workers and within communities, underscoring the urgent need for effective containment measures and enhanced healthcare responses. This outbreak not only affects the immediate populations in DR Congo and Uganda but also poses a risk of wider regional and international spread, given the interconnectedness of health systems and travel. The WHO's declaration emphasizes the need for global attention and resources to combat the outbreak and improve preparedness for future epidemics. As the situation develops, healthcare professionals and public health officials are urged to monitor the outbreak closely and implement necessary interventions to mitigate the spread of the virus. The response will likely involve increased surveillance, vaccination efforts, and community engagement to ensure that the outbreak is contained effectively.

The Lancet · 2d ago

17th Ebola Outbreak in DRC Raises Global Health Concerns Amidst Local Instability

The Democratic Republic of the Congo (DRC) has declared its 17th outbreak of Ebola virus disease, prompting urgent global health concerns. This outbreak is particularly alarming due to its potential to spread into neighboring Uganda and is occurring in a context marked by chronic insecurity, significant population displacement, and limited diagnostic capabilities. Preliminary epidemiological data suggest that the outbreak is linked to a non-Zaire orthoebolavirus genotype, likely the Bundibugyo virus. Historically, Bundibugyo virus has been associated with a lower case fatality rate ranging from 14% to 63% compared to the Zaire ebolavirus, which has a fatality rate between 63% and 87%. However, recent field observations indicate a troubling mortality rate exceeding 90 suspected deaths as of May 18, 2026. This situation underscores the need for immediate intervention and support from global health organizations to contain the outbreak and mitigate its impact on the affected populations. The ongoing challenges in the region, including insecurity and healthcare access, complicate response efforts and highlight the importance of international collaboration in addressing such syndemic challenges.

The Lancet · 2d ago

ReDLat2 Initiative Explores Genetic and Environmental Factors in Dementia Across Latin America

The ReDLat2 initiative emphasizes the importance of studying genetic and environmental interactions in dementia research, particularly in Latin American populations. Current research predominantly focuses on individuals of European ancestry, which limits the understanding of dementia risk factors in diverse populations. This initiative aims to bridge the gap by incorporating the exposome—environmental factors accumulated over a lifetime—into dementia studies. Dementia, including Alzheimer’s disease and frontotemporal lobar degeneration, poses a significant burden in Latin America, where genetic diversity and varying environmental conditions complicate the landscape of risk and resilience. The initiative highlights the need for a more inclusive approach that considers social determinants of health, such as socioeconomic status, nutrition, and environmental quality, as integral components of dementia research rather than mere covariates. Key funding for the ReDLat2 initiative comes from the US National Institute on Aging and various international organizations, underscoring a collaborative effort to enhance understanding and treatment of dementia in underrepresented populations. The initiative aims to develop predictive models and risk assessment tools tailored to the unique challenges faced by Latin American communities, ultimately improving diagnosis and treatment access. As the initiative progresses, it is expected to yield valuable insights that could inform public health strategies and clinical practices, addressing the disparities in dementia care and research across different populations.

Nature Medicine · 3d ago

Case Study: 64-Year-Old Woman with Fatigue, Cognitive Decline, and Fall Incidents

A recent case published in the New England Journal of Medicine details the medical journey of a 64-year-old woman presenting with fatigue, memory changes, and recurrent falls. These symptoms raised concerns about potential underlying neurological or systemic conditions. The case highlights the importance of thorough clinical evaluation in older adults, particularly when multiple symptoms are present, as they can indicate serious health issues that require prompt intervention. The patient's history and clinical findings prompted a series of diagnostic tests, which are crucial in determining the underlying cause of her symptoms. This case serves as a reminder of the complexities involved in geriatric care, where symptoms may overlap with normal aging processes or indicate more severe conditions such as neurodegenerative diseases or metabolic disorders. Healthcare professionals are encouraged to consider a comprehensive approach when assessing similar cases, as early diagnosis and management can significantly impact patient outcomes. The findings from this case may lead to further research into the diagnostic pathways for similar presentations in older populations, emphasizing the need for continued education and awareness in geriatric medicine.

NEJM · 4d ago

Successful Resolution of PML Following Virus-Specific T Cell Therapy and Hematopoietic Cell Transplantation

A recent study published in the New England Journal of Medicine details a case of progressive multifocal leukoencephalopathy (PML) successfully treated with virus-specific T cells and hematopoietic cell transplantation (HCT). PML, a rare but serious demyelinating disease caused by the JC virus, poses significant risks, particularly in immunocompromised patients. The innovative approach demonstrated in this case highlights the potential of targeted immunotherapy in managing viral infections that lead to severe neurological complications. The patient, who had a history of immunosuppression, showed marked improvement following the administration of virus-specific T cells, which were engineered to target the JC virus. This treatment was complemented by HCT, which further enhanced the patient's immune response. The resolution of PML symptoms and the restoration of neurological function underscore the importance of advancing therapeutic strategies for viral infections in vulnerable populations. This case not only provides hope for patients suffering from PML but also emphasizes the need for ongoing research into the efficacy of T cell therapies in treating viral diseases. As healthcare professionals continue to explore the implications of this treatment, it may pave the way for new protocols in managing similar cases, potentially improving outcomes for patients with compromised immune systems. Future studies will be essential to validate these findings across larger cohorts and to establish standardized treatment regimens. The success of this case could lead to broader applications of virus-specific T cell therapies in various viral infections, marking a significant advancement in the field of infectious disease management.

NEJM · 4d ago

Advancements in Hematopoietic Stem-Cell Gene Therapy for Cystinosis Reported

A recent publication in the New England Journal of Medicine highlights significant progress in hematopoietic stem-cell gene therapy for cystinosis, a rare genetic disorder characterized by the accumulation of cystine in lysosomes, leading to multi-organ damage. This innovative therapy aims to address the underlying genetic defect by introducing a functional copy of the cystine transporter gene into the patient's hematopoietic stem cells. The implications of this research are profound, as it offers a potential curative approach for patients who currently rely on lifelong cystine-depleting therapies. The study's findings could pave the way for clinical trials and further investigations into the efficacy and safety of this treatment modality. As the medical community continues to explore gene therapy options, cystinosis patients and their families may soon have new hope for improved health outcomes.

NEJM · 4d ago

Comparative Study on Decompression Techniques for Chiari I Malformation and Syringomyelia

A recent study published in the New England Journal of Medicine evaluates the efficacy of decompression surgery with and without duraplasty for patients suffering from Chiari I malformation and syringomyelia. This research is significant as it addresses a common surgical dilemma faced by neurosurgeons regarding the optimal approach to alleviate symptoms associated with these conditions. The study involved a cohort of patients who underwent decompression surgery, with outcomes measured in terms of symptom relief and postoperative complications. The findings indicate that while both techniques provide symptom relief, the addition of duraplasty may not significantly enhance outcomes compared to decompression alone. This is crucial for healthcare professionals as it could influence surgical decision-making and patient counseling regarding the risks and benefits of each approach. The study's results are expected to impact clinical practices and guidelines for treating Chiari I malformation and syringomyelia. As the research continues to gain attention, further investigations may be warranted to explore long-term outcomes and the potential for personalized treatment strategies. The implications of this study extend to neurosurgeons, patients, and healthcare systems, emphasizing the need for evidence-based practices in surgical interventions for these neurological conditions.

NEJM · 4d ago

Advancements in Secondary Prevention Strategies Following Ischemic Stroke

Recent findings published in the New England Journal of Medicine highlight the importance of secondary prevention strategies for patients who have experienced an ischemic stroke. These strategies are crucial in reducing the risk of subsequent strokes and improving long-term outcomes for affected individuals. The study emphasizes the need for healthcare professionals to implement evidence-based interventions, including antiplatelet therapy, lifestyle modifications, and management of comorbid conditions such as hypertension and diabetes. The research underscores that approximately 25% of stroke survivors will experience another stroke within five years, making effective secondary prevention essential. Key data from the study indicate that adherence to prescribed medications and lifestyle changes can significantly lower the recurrence rate. This is particularly relevant for healthcare providers who are tasked with educating patients on the importance of ongoing management and follow-up care. As the healthcare community continues to address the burden of stroke, these findings will inform clinical guidelines and patient care protocols. The emphasis on secondary prevention not only aims to enhance patient quality of life but also to reduce healthcare costs associated with recurrent strokes. Moving forward, further research will be necessary to explore innovative approaches and interventions that can be integrated into routine care for stroke survivors.

NEJM · 4d ago

Study Evaluates Zanidatamab and Tislelizumab in HER2-Positive Gastroesophageal Cancer

A recent study published in the New England Journal of Medicine investigates the efficacy of zanidatamab, both alone and in combination with tislelizumab, in treating HER2-positive gastroesophageal cancer. This research is significant as HER2-positive gastroesophageal cancer is known for its aggressive nature and poor prognosis, making effective treatment options critical for patient outcomes. The study's findings could potentially reshape treatment protocols and improve survival rates for affected patients. The trial involved a diverse cohort of patients diagnosed with HER2-positive gastroesophageal cancer, assessing the response rates and overall survival associated with the two treatment regimens. Preliminary results indicate that the combination therapy may enhance therapeutic efficacy compared to zanidatamab alone, suggesting a synergistic effect that warrants further investigation. Healthcare professionals should note the implications of these findings for clinical practice, particularly in tailoring treatment strategies for patients with this challenging cancer type. As the study progresses, additional data on long-term outcomes and side effects will be crucial in determining the best course of action for patients. Future research may also explore the potential for zanidatamab and tislelizumab in other cancer types, expanding their therapeutic applications.

NEJM · 4d ago

Innovative Approaches to Remuscularize the Failing Human Heart

Recent research published in the New England Journal of Medicine explores novel strategies aimed at remuscularizing the failing human heart. This study highlights the potential of regenerative therapies to restore cardiac function in patients suffering from heart failure, a condition that affects millions globally and is a leading cause of morbidity and mortality. The findings suggest that targeted interventions could significantly improve patient outcomes by enhancing myocardial repair and regeneration. As heart failure continues to pose a substantial burden on healthcare systems, these advancements could pave the way for new treatment protocols and improve the quality of life for affected individuals. Future research will focus on clinical trials to validate these approaches and assess their long-term efficacy and safety.

NEJM · 4d ago

Utah's AI Sandbox Highlights Need for Ongoing Oversight in Clinical AI Regulation

The regulation of autonomous clinical artificial intelligence (AI) faces significant challenges, particularly in the context of evolving technologies. Traditional regulatory frameworks, such as those established by the US Food and Drug Administration (FDA), are primarily designed for static medical devices and algorithms. This creates a governance mismatch as modern clinical AI systems are dynamic and can change in performance due to various factors, including shifts in patient populations and updates to clinical guidelines. As a result, even AI systems that pass initial evaluations may quickly become outdated, necessitating a reevaluation of regulatory practices. The implications of this issue are profound, affecting healthcare providers, patients, and regulatory bodies alike. With AI systems increasingly integrated into clinical workflows, the need for continuous monitoring and assessment is critical to ensure patient safety and efficacy of care. The current regulatory landscape does not adequately address the need for ongoing oversight, which could lead to potential risks if AI systems are not regularly updated or evaluated. Key stakeholders, including healthcare professionals and policymakers, must collaborate to develop a framework that accommodates the unique characteristics of AI technologies. This may involve establishing new guidelines for continuous performance evaluation and creating partnerships between regulatory agencies and AI developers. As the healthcare landscape continues to evolve with technological advancements, proactive measures will be essential to safeguard public health and maintain trust in AI applications in medicine.

Nature Medicine · 4d ago

Unvaccinated Blood Donations May Delay Care and Compromise Patient Safety

A recent review published in the journal Transfusion highlights the potential risks associated with blood requests from unvaccinated donors. The study indicates that reliance on blood from individuals who have not received vaccinations could lead to significant delays in patient care and may adversely affect health outcomes. This issue is particularly pressing as healthcare systems continue to navigate the complexities of managing blood supplies amid ongoing public health challenges. The findings underscore the importance of vaccination in ensuring a safe and reliable blood supply, which is critical for various medical procedures and emergency situations. As healthcare professionals assess the implications of these findings, there may be a need for revised protocols regarding blood donation eligibility and increased public health campaigns to encourage vaccination among potential donors.

JAMA Network · 5d ago

AI as a Tool to Alleviate Physician Administrative Burdens

A recent viewpoint discusses the role of artificial intelligence (AI) in healthcare, emphasizing its potential to reduce the administrative workload of physicians. By automating routine tasks, AI can allow healthcare providers to focus more on patient care, thereby enhancing the quality of service delivered to patients. This shift is particularly important as physicians often face burnout due to excessive paperwork and administrative duties, which detracts from their primary role of patient interaction and treatment. The integration of AI tools could lead to improved job satisfaction among healthcare professionals and better outcomes for patients. As AI technology continues to evolve, its implementation in clinical settings will likely expand, necessitating ongoing training and adaptation for healthcare providers to maximize its benefits.

JAMA Network · 5d ago

Six-Month Outcomes of Potassium Supplementation Post-Cardiac Surgery Revealed in TIGHT K Trial

The TIGHT K randomized clinical trial has published its prespecified six-month follow-up outcomes regarding potassium supplementation thresholds in patients following cardiac surgery. This study is significant as it addresses the critical balance of potassium levels in post-operative care, which can impact recovery and overall patient outcomes. The findings are particularly relevant for cardiologists and surgical teams who manage post-operative care in cardiac patients. Key data from the trial will inform best practices for potassium supplementation, potentially leading to improved recovery protocols. As the healthcare community awaits further analysis, the implications of these findings could influence guidelines for managing electrolyte levels in post-surgical patients.

JAMA Network · 5d ago

Proposed Licensure Framework for Autonomous Clinical AI Amid Workforce Shortage

A new perspective has emerged regarding the licensure of autonomous clinical artificial intelligence (AI) systems, particularly in response to the ongoing shortage of clinical care professionals. As healthcare systems face increasing demands and a dwindling workforce, the integration of AI technologies could provide essential support in clinical settings. This proposed framework aims to establish guidelines for the safe and effective deployment of AI in patient care, ensuring that these systems meet necessary standards for reliability and ethical considerations. The significance of this framework lies in its potential to alleviate some of the pressures on healthcare providers by allowing AI to assist in various clinical tasks, thereby improving efficiency and patient outcomes. By defining clear licensure requirements, stakeholders can foster trust in AI technologies, which is crucial for their acceptance and integration into everyday clinical practice. Healthcare professionals, regulatory bodies, and technology developers are the primary stakeholders affected by this initiative. The framework could lead to a more structured approach to AI implementation, ensuring that all parties are aligned on safety and efficacy standards. As AI continues to evolve, ongoing discussions and revisions to the licensure framework will be necessary to keep pace with technological advancements and the changing landscape of healthcare delivery. Looking ahead, the successful establishment of this licensure framework could pave the way for broader adoption of AI in clinical settings, ultimately addressing workforce shortages and enhancing patient care. Continuous collaboration among healthcare professionals, AI developers, and regulatory agencies will be essential to navigate the complexities of integrating AI into clinical practice effectively.

JAMA Network · 5d ago

Efficacy of Cardiac Resynchronization Therapy in Patients with Dyssynchrony Reviewed

A recent narrative review has evaluated the effectiveness of cardiac resynchronization therapy (CRT), focusing on both biventricular pacing and conduction system pacing. This therapy is primarily aimed at patients suffering from cardiac dyssynchrony, which often arises from conduction system diseases. The review highlights the importance of CRT in improving cardiac function and patient outcomes, particularly in those with heart failure and associated conduction abnormalities. The significance of this review lies in its comprehensive analysis of existing studies, which collectively suggest that CRT can lead to substantial improvements in symptoms and quality of life for patients. It underscores the need for healthcare professionals to consider CRT as a viable treatment option for eligible patients, especially as advancements in pacing technology continue to evolve. Key data from the review indicate that patients receiving CRT often experience enhanced left ventricular function and reduced hospitalizations due to heart failure. The findings are particularly relevant for cardiologists and healthcare providers involved in the management of heart failure, as they provide evidence-based insights into the benefits of CRT. Looking ahead, the review calls for further research to optimize patient selection for CRT and to explore the long-term outcomes associated with different pacing strategies. As the field of cardiac therapy progresses, understanding the nuances of CRT will be crucial for improving patient care and outcomes in those affected by cardiac dyssynchrony.

JAMA Network · 5d ago

CDC Reports Significant Increase in Extensively Drug-Resistant Shigella Infections

The US Centers for Disease Control and Prevention (CDC) has released alarming data indicating a notable rise in cases of extensively drug-resistant Shigella infections since 2015. This trend poses a serious public health challenge, as Shigella is a common cause of bacterial diarrhea, particularly affecting children and immunocompromised individuals. The increase in drug resistance complicates treatment options and raises concerns about the potential for widespread outbreaks. Healthcare professionals must remain vigilant in monitoring cases and implementing effective infection control measures. The CDC's findings underscore the urgent need for enhanced surveillance and research into new treatment strategies to combat this growing threat.

JAMA Network · 5d ago

Phase 2 Trial Shows Promise of Rogaratinib for SDH-Deficient Gastrointestinal Stromal Tumors

A recent phase 2 trial evaluated the efficacy of rogaratinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs). These tumors, which account for 10-15% of GIST cases, are characterized by functional loss of the SDH complex and significant DNA hypermethylation, leading to aberrant expression of oncogenic ligands such as FGF3 and FGF4. The trial aimed to estimate the objective response rate, progression-free survival (PFS), and assess safety and tolerability in a cohort of 24 patients enrolled across 11 centers in the USA. Results indicated that 41.7% of patients experienced partial responses to rogaratinib, with a median PFS of 31.0 months and a 1-year PFS rate of 77.4%. The treatment was generally well-tolerated, with manageable side effects including hyperphosphatemia, fatigue, and diarrhea. Notably, elevations in phosphorous levels were consistent with FGFR1 target engagement, supporting the drug's mechanism of action. Whole-exome sequencing confirmed expected alterations in SDH subunit coding genes, reinforcing the trial's focus on epigenetic mechanisms driving oncogenesis in these tumors. This trial underscores the potential of targeted therapies based on epigenetic alterations, marking a significant step forward in the treatment of SDH-deficient GISTs, which have historically shown limited response to conventional therapies. The findings may pave the way for further research into FGFR inhibitors and their role in managing other cancers characterized by similar epigenetic changes.

Nature Medicine · 5d ago

New Lancet Commission Aims for Equitable Adoption of Precision Health Globally

The Lancet Commission on precision health has been launched as a global initiative to evaluate and enhance the adoption of precision health strategies across health systems worldwide. This initiative is particularly significant as it seeks to ensure that advancements in precision health are accessible and equitable, addressing disparities in healthcare delivery. The Commission will work in alignment with other major health initiatives, including the World Health Organization's upcoming 2026 draft resolution on precision medicine. Key outputs from the Commission will include the development of precision health frameworks that can be tailored to fit the unique contexts of various populations. This includes taking into account the specific disease burdens, as well as the cultural, economic, and social characteristics that influence health outcomes in different regions. By focusing on these factors, the Commission aims to create actionable recommendations that can be implemented by health systems globally. The implications of this initiative are far-reaching, as it seeks to bridge the gap between cutting-edge medical advancements and the populations that stand to benefit from them. Healthcare professionals, policymakers, and organizations involved in health equity will be particularly affected, as the Commission's findings could shape future healthcare policies and practices. As the Commission progresses, stakeholders will be looking for guidance on how to effectively integrate precision health into existing frameworks to improve health outcomes for all.

The Lancet · 6d ago

WHO Declares PHEIC for Bundibugyo Virus Ebola Outbreak, Highlighting Global Health Inequities

On May 16, 2026, the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) regarding the Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of Congo (DRC) and Uganda. This declaration, made by WHO Director-General Tedros Adhanom Ghebreyesus, marks a significant procedural deviation as it was issued without convening an Emergency Committee, reflecting the severity of the situation. The outbreak is attributed to longstanding issues such as chronic underinvestment in local health systems and a global neglect of pathogens that primarily impact lower-income nations. The declaration of a PHEIC is a critical step in mobilizing international support and resources to combat the outbreak. It underscores the urgent need for solidarity and health equity, particularly in regions that have historically been overlooked in global health initiatives. The Bundibugyo virus, a member of the Orthoebolavirus genus, poses a serious threat to public health, and the current outbreak could have far-reaching implications if not addressed promptly. Healthcare professionals and policymakers are now called to action to strengthen health systems in affected areas and ensure that adequate resources are allocated to combat this outbreak. The situation serves as a reminder of the importance of global cooperation in addressing health crises, particularly those that disproportionately affect vulnerable populations. As the world responds to this emergency, the focus will be on implementing effective containment strategies and enhancing local healthcare capabilities to prevent future outbreaks.

The Lancet · 6d ago

Hantavirus Case Reported on Cruise Ship at Ascension Island Raises Health Concerns

On April 27, 2026, the MV Hondius, a Dutch-flagged expedition cruise ship, docked at Ascension Island, a remote UK Overseas Territory. During its journey from Ushuaia, Argentina, the ship visited several locations including the Antarctic Peninsula and other islands in the South Atlantic. Upon arrival, a 69-year-old male passenger was admitted to the local medical facility with severe respiratory symptoms, raising alarms about a potential hantavirus outbreak. Hantavirus is known to cause severe respiratory illness and can be transmitted through contact with infected rodents or their droppings. The case has prompted health officials to investigate the situation further, as the island's healthcare resources are limited. The implications of this case are significant, not only for the affected individual but also for the local community and other passengers who may have been exposed. Authorities are monitoring the situation closely and are expected to implement preventive measures to mitigate any potential spread of the virus.

The Lancet · 6d ago

AI Implementation in Healthcare Exacerbates Inequities, Study Reveals

A recent analysis published in The Lancet highlights the concerning trend of artificial intelligence (AI) implementation in healthcare, revealing that its distribution is uneven across the United States. The study examined 3,560 hospitals and found that regions with the greatest healthcare needs are less likely to have adopted AI technologies. This phenomenon echoes Julian Tudor Hart's 'inverse care law,' which posits that access to medical care is inversely related to need. The implications of this trend are significant, as AI has the potential to enhance patient care and operational efficiency. However, if its benefits are not equitably distributed, existing health disparities may be exacerbated. Healthcare professionals and policymakers must address these inequities to ensure that advancements in AI do not reinforce existing barriers to care. Moving forward, it is crucial to develop strategies that promote equitable access to AI technologies in all regions, particularly those with higher healthcare needs.

The Lancet · May 22

Semaglutide Shows Promise for Weight Loss in Patients with Suboptimal Response Post-Bariatric Surgery

A recent double-blind, randomized, placebo-controlled trial, known as the BARI-STEP trial, is investigating the efficacy of semaglutide 2.4 mg in patients who have experienced suboptimal weight loss following metabolic and bariatric surgery (MBS). Obesity, which contributes to approximately 3.7 million deaths annually, remains a significant global health challenge. While MBS is the most effective long-term treatment for severe obesity, around 20% of patients do not achieve optimal weight loss, leading to the resurgence of obesity-related comorbidities such as type 2 diabetes (T2D). The BARI-STEP trial aims to address this gap by evaluating semaglutide, a GLP-1 receptor agonist, as a potential adjunct therapy for these patients. The trial will assess the impact of semaglutide on weight loss and metabolic health over 68 weeks, focusing on various outcomes including percentage weight loss, the proportion of patients achieving significant weight loss categories, and improvements in quality of life. Previous studies, including the BARI-OPTIMISE trial, have shown that liraglutide can improve weight loss and metabolic outcomes in similar populations, but semaglutide has demonstrated superior efficacy in broader obesity management contexts. The BARI-STEP trial is particularly significant as it is the first to evaluate semaglutide specifically in patients with inadequate weight loss post-MBS. Conducted from November 2022 to April 2025, the trial has pre-screened 128 participants, with 70 eligible individuals enrolled. The findings from this study could potentially reshape treatment strategies for patients struggling with weight management after bariatric surgery, offering a new pharmacological option to enhance the benefits of surgical interventions. As the prevalence of obesity continues to rise, effective management strategies are critical for improving patient outcomes and reducing the burden of obesity-related diseases.

Nature Medicine · May 22

Rising Awareness of Coronary Microvascular Dysfunction in Chronic Coronary Syndromes

Recent advancements in understanding myocardial ischemia have highlighted the significance of non-obstructive causes, particularly coronary microvascular dysfunction (CMD), in patients experiencing anginal symptoms. Over the last two decades, it has become increasingly clear that CMD plays a crucial role in the pathophysiology of chronic coronary syndromes, affecting millions of individuals worldwide. In 2023, both American and European clinical practice guidelines have begun to emphasize the importance of recognizing CMD and vasomotor disorders as potential contributors to these syndromes. The guidelines advocate for the use of functional coronary testing to accurately diagnose CMD and to identify the predominant mechanisms or endotypes of vascular dysfunction. This shift in clinical practice is essential as it allows for more tailored treatment approaches, potentially improving patient outcomes. Healthcare professionals are urged to consider these non-obstructive causes when evaluating patients with chronic coronary syndromes, as traditional diagnostic methods may overlook CMD. The integration of these guidelines into clinical practice could lead to a significant change in how myocardial ischemia is managed, ultimately benefiting a large patient population suffering from chronic coronary conditions.

The Lancet · May 21

Coronary Microvascular Dysfunction Linked to Increased Cardiovascular Risks in South Korean Patients

A recent study from the FLOW-CMD Registry in South Korea has revealed significant findings regarding coronary microvascular dysfunction (CMD) in patients with suspected ischemic heart disease. The research indicates that CMD often coexists with epicardial coronary artery disease and is associated with a heightened risk of adverse cardiovascular outcomes. Specifically, patients exhibiting CMD were found to have an increased likelihood of experiencing a composite of all-cause mortality, myocardial infarction, repeat revascularization driven by clinical necessity, and hospitalizations due to heart failure. This study is crucial as it highlights the importance of recognizing CMD in the clinical assessment of patients undergoing invasive coronary angiography. The implications of these findings are significant for healthcare professionals, as they suggest that CMD should be considered a critical factor in the management and treatment strategies for patients with coronary artery disease. By identifying CMD, clinicians may be able to better stratify risk and tailor interventions to improve patient outcomes. The study's findings underscore the need for further research into the mechanisms underlying CMD and its relationship with traditional coronary artery disease. As healthcare systems continue to evolve, understanding the full spectrum of coronary pathophysiology will be essential in enhancing patient care and reducing cardiovascular morbidity and mortality. Future studies may focus on therapeutic approaches targeting CMD to mitigate its associated risks.

The Lancet · May 21

Enhancing U = U Awareness: A Call for Equity in HIV Prevention Strategies

Recent advancements in antiretroviral therapy (ART) have significantly increased global HIV suppression rates, rising from 40% in 2015 to 73% in 2024. This progress supports the 'Undetectable = Untransmittable' (U = U) message, which asserts that individuals with sustained viral suppression pose no risk of transmitting HIV. However, awareness and understanding of U = U remain uneven across different populations and regions, highlighting a critical need for culturally tailored interventions and improved healthcare provider education. A meta-analysis involving approximately 227,000 participants revealed that while awareness of U = U is high among people living with HIV (PLHIV), it is moderate among men who have sex with men (MSM) and low in the general population. For instance, a study in Brazil found that 79% of PLHIV recognized U = U as accurate, compared to only 44% of MSM not living with HIV and 17% of the general population. Geographical disparities further complicate the issue, with higher awareness reported in high-income settings compared to low-income regions, particularly in sub-Saharan Africa, where women and girls represent a significant proportion of new HIV diagnoses. Social determinants of health, such as income and education, also play a role in U = U literacy. Studies indicate that individuals with higher income and education levels are more likely to understand and accept U = U. Conversely, healthcare providers, despite increased awareness, often hesitate to communicate the U = U message clearly, fearing misinterpretation by patients. This reluctance can perpetuate outdated fears surrounding HIV transmission, underscoring the need for comprehensive education and supportive policy environments to promote equitable access to U = U knowledge and its associated health benefits.

PLOS Medicine · May 21

New Symptoms Linked to Eclampsia Could Enhance Detection and Save Maternal Lives

A recent study published in PLOS Medicine has identified ten novel prodromal symptoms associated with eclampsia, which could significantly improve early detection and management of this severe condition. Eclampsia, a serious complication of pre-eclampsia, poses a high risk of maternal mortality, particularly in low- and middle-income countries (LMICs) where healthcare resources are limited. Current management strategies primarily involve the use of magnesium sulfate, which reduces the risk of eclampsia, but the identification of women at high risk remains a challenge due to inadequate diagnostic tools and healthcare infrastructure. The study, conducted over five years in South Africa and Pakistan, involved women with eclampsia, pre-eclampsia, or normotensive pregnancies. Researchers found that traditional symptoms such as headache and visual changes had limited predictive value for eclampsia onset. In contrast, the newly identified symptoms exhibited much stronger associations, with odds ratios exceeding 10, indicating a significant correlation with the onset of eclampsia. This advancement is crucial as it could lead to better triaging of patients, optimizing the timing of delivery, and ultimately reducing maternal and fetal mortality rates. Given that hypertensive disorders of pregnancy are the leading cause of maternal deaths, particularly in LMICs where 95% of these deaths occur, the implications of this research are profound. The findings underscore the urgent need for improved prognostic tools that can be implemented in resource-limited settings. As healthcare professionals seek to enhance maternal care, these novel symptoms may provide a more reliable framework for identifying women at risk and ensuring timely interventions, thereby saving lives.

PLOS Medicine · May 21

Longitudinal Study Reveals Trends in Hormonal Contraceptive Use in Estonia

A recent longitudinal study utilizing data from the Estonian Biobank (EstBB) has provided new insights into the trends of hormonal contraceptive (HC) use among women aged 15-55 in Estonia from 2004 to 2022. The study analyzed the purchase records of 73,071 female HC users, revealing that 64.2% switched formulations at least once, with 17.7% identified as rapid switchers. The findings indicate that combined hormonal contraceptives were predominantly used by younger women, while progestin-only formulations gained popularity with age. The research also highlighted a concerning link between genetic factors and side effects associated with HC use. Among rapid switchers, 23.1% experienced side effect-related diagnoses, with excessive or irregular menstrual bleeding being the most common. Genetic analysis showed that 5.3% of users carried variants associated with increased thrombosis risk, and these carriers had a higher incidence of thrombosis compared to non-carriers (6.5% vs. 4.2%). This study underscores the importance of understanding the interplay between genetics and hormonal contraceptive use, which could lead to improved prescribing practices. The EstBB dataset offers a robust framework for future pharmacogenetic studies, although limitations exist regarding the accuracy of purchase records in reflecting actual HC use. The findings may not be generalizable to women outside Estonia due to variations in HC use across different countries. As the research community continues to explore the genetic underpinnings of HC side effects, this study serves as a valuable resource for understanding user profiles and the implications of rapid formulation switching. Future studies could replicate this approach in other biobanks to validate these findings across diverse populations.

PLOS Medicine · May 20

Global Efforts to Combat Infectious Diseases Face Significant Challenges Amidst Fragmentation

A recent special issue highlights the ongoing challenges and opportunities in the fight against infectious diseases in a world marked by fragmentation and conflict. Despite previous successes in eradicating diseases like measles and polio, countries such as Canada and the UK have lost their elimination status, with the USA also at risk. The article emphasizes the multifaceted barriers to eradication, including shifts in research funding, the withdrawal of the USA from the World Health Organization, and cuts to UNAIDS funding, which could lead to millions of new HIV infections and deaths by 2030. The impact of global fragmentation, escalating conflicts, and climate change further complicates efforts to control infectious diseases. However, there are notable successes, such as Brazil's announcement of eliminating mother-to-child HIV transmission by 2025, attributed to its robust universal health system and community engagement. The article also discusses the ongoing development of tuberculosis vaccines, including the promising M72/AS01 vaccine, which could significantly aid in tuberculosis elimination efforts. Additionally, the HPV vaccine has shown remarkable efficacy, with a 79% drop in cervical pre-cancer rates in the USA from 2008 to 2022. Despite these advancements, challenges remain, including vaccine hesitancy and access disparities exacerbated by funding cuts. The Africa CDC's initiatives to enhance outbreak preparedness and self-reliance in response to diseases like mpox and cholera are also highlighted, emphasizing the need for increased surveillance and data sharing to improve outbreak responses. Overall, while the landscape is fraught with difficulties, recent progress in vaccines and therapeutics offers hope for future disease control and eradication.

Nature Medicine · May 20

Regulatory Changes Threaten Progress in Digital Pathology Post-COVID-19

The COVID-19 pandemic accelerated the adoption of digital tools in pathology, allowing for remote diagnostic workflows that enhanced patient care and access to subspecialty expertise. Temporary regulatory flexibility enabled pathologists to conduct cytology reviews, such as Pap smears, remotely, which proved beneficial during workforce shortages and improved diagnostic efficiency. However, recent regulatory guidance has imposed restrictions on these practices, raising concerns about the impact of legacy oversight on modern clinical practices. This shift could hinder the advancements made in digital medicine, potentially affecting patient outcomes and access to timely diagnostics. As healthcare professionals navigate these changes, the need for updated regulations that reflect current technological capabilities becomes increasingly critical.

Nature Medicine · May 20

HPV Vaccines: Two Decades of Impact and Ongoing Challenges in Cancer Control

As the HPV vaccine marks its 20th anniversary, it has become a cornerstone in the global fight against cervical cancer. Women are increasingly recognized as central to cancer control efforts, yet significant challenges remain in achieving widespread vaccination and screening. The World Health Organization (WHO) has set ambitious goals to eliminate cervical cancer as a public health problem, but disparities in vaccine access and uptake persist, particularly in low- and middle-income countries. Recent studies highlight the effectiveness of HPV vaccination in reducing cervical cancer incidence, with data showing a marked decline in cases among vaccinated populations. However, global vaccination rates remain uneven, with only a fraction of eligible girls receiving the vaccine in many regions. The WHO's Global Strategy aims to accelerate the elimination of cervical cancer, emphasizing the need for comprehensive vaccination programs and improved screening methods. Healthcare professionals and policymakers are urged to address these disparities by expanding access to HPV vaccines and enhancing public awareness campaigns. The ongoing efforts to eliminate cervical cancer will require collaboration across sectors, including government, healthcare providers, and community organizations. As the landscape of HPV vaccination evolves, continuous monitoring and adaptation of strategies will be essential to meet the WHO's targets and protect future generations from cervical cancer.

Nature Medicine · May 20

Impact of Climate Change on Infectious Disease Dynamics: A Growing Concern

Recent studies highlight the significant influence of climate change on the dynamics of infectious diseases globally. As temperatures rise and weather patterns shift, the geographical distribution and incidence of diseases such as malaria, dengue, and cholera are being altered, posing new challenges for public health. For instance, research indicates that climate warming is expanding the burden of dengue in the Americas and Asia, while malaria transmission potential may shift towards arboviruses in Africa due to changing environmental conditions. The implications of these findings are profound, as they suggest that climate change could exacerbate existing health disparities and increase the burden on healthcare systems, particularly in low- and middle-income countries. Key data from the Global Burden of Disease Study indicates that the burden of malaria has been significantly affected by the COVID-19 pandemic, complicating efforts to control this disease. Moreover, the role of humidity and temperature in the transmission of various pathogens, including influenza and SARS-CoV-2, underscores the need for a comprehensive understanding of how environmental factors influence disease spread. As researchers continue to explore these relationships, it becomes increasingly clear that addressing climate change is not only an environmental imperative but also a critical component of global health strategy. Moving forward, public health officials and policymakers must prioritize climate adaptation strategies to mitigate the risks associated with infectious diseases. This includes enhancing surveillance systems, investing in vector control measures, and promoting community awareness to prepare for the health impacts of a changing climate.

Nature Medicine · May 20

Addressing Inequities in Humanitarian Aid: A Call for Systemic Change

The humanitarian system, often viewed as a source of hope during crises, is increasingly criticized for perpetuating inequities rooted in colonial histories and global power imbalances. Despite its mission to alleviate suffering, the system frequently reinforces the very disparities it aims to address, affecting the most vulnerable populations. This critique highlights the need for a transformative approach to humanitarian aid that challenges existing policies and frameworks, as well as the interpersonal and cultural practices that marginalize those in need. As humanitarian professionals reflect on their roles, there is a growing consensus that systemic change is essential to create a more equitable and effective aid system. The call to action emphasizes the importance of recognizing and dismantling these embedded inequities to fulfill the true purpose of humanitarian work.

The Lancet · May 19

Paul B Spiegel: A Leader in Humanitarian Health and Conflict Response

Paul B Spiegel, a prominent figure in humanitarian health, has made significant contributions to the field through his dual role in academia and practical application. As Co-Chair of the Johns Hopkins Center for Humanitarian Health–Lancet Commission on Health, Conflict, and Forced Displacement, Spiegel is recognized for his unique ability to bridge the gap between theoretical knowledge and real-world challenges. His journey into this vital area of healthcare began in his youth, inspired by a TIME magazine article on Médecins Sans Frontières (MSF), which motivated him to pursue a career in medicine. Spiegel's work is particularly relevant in today's global landscape, where conflicts and forced displacement are increasingly prevalent. His insights and research are crucial for understanding the health implications of these crises and developing effective responses. The humanitarian health sector faces numerous challenges, including resource allocation, access to care, and the integration of health services in conflict zones, all of which Spiegel addresses through his work. As the world grapples with ongoing humanitarian crises, the expertise of leaders like Spiegel is essential for shaping policies and practices that can improve health outcomes for affected populations. His commitment to humanitarian health not only influences academic discourse but also has a tangible impact on the ground, where health professionals strive to provide care in some of the most challenging environments. Looking ahead, Spiegel's continued advocacy and research will be vital in addressing the evolving needs of communities affected by conflict and displacement.

The Lancet · May 19

Global Commitment to Combat Antimicrobial Resistance Set at 2024 UN General Assembly

During the 2024 UN General Assembly (UNGA) high-level meeting, member countries reached a unanimous agreement to tackle antimicrobial resistance (AMR) by setting ambitious targets aimed at reducing global mortality associated with bacterial AMR by 10% by the year 2030, using 2019 figures as a baseline. This commitment highlights the urgent need to address the growing threat of AMR, which poses significant risks to public health worldwide. In addition to the mortality reduction target, the UNGA endorsed a crucial goal that by 2030, at least 70% of human antibiotic use globally should consist of Access antibiotics. These are classified by the World Health Organization (WHO) as first-line treatments for common infections and are associated with a lower risk of developing resistance. This initiative is part of the AWaRe (Access, Watch, Reserve) framework, which aims to ensure the responsible use of antibiotics and preserve their effectiveness. The implications of these targets are profound, as they not only aim to save lives but also to promote the sustainable use of antibiotics in healthcare settings. The commitment from countries reflects a growing recognition of the need for coordinated global action to combat AMR, which threatens to undermine decades of medical advancements. Moving forward, healthcare professionals and policymakers will need to collaborate closely to implement strategies that meet these targets, including improving access to essential antibiotics, enhancing surveillance of antibiotic use, and promoting public awareness about the responsible use of these critical medications. The success of these initiatives will be vital in safeguarding public health and ensuring effective treatment options for future generations.

The Lancet · May 19

Johns Hopkins-Lancet Commission Addresses Health Challenges Amid Conflict and Displacement

The Johns Hopkins Center for Humanitarian Health, in collaboration with The Lancet, has released a comprehensive report focusing on the intersection of health, conflict, and forced displacement. This commission highlights the urgent health crises faced by populations affected by war and displacement, emphasizing the need for immediate action and policy reform. The report underscores the significant health disparities that arise in conflict zones, where access to essential healthcare services is severely compromised. It also calls attention to the long-term implications of these crises on public health systems and the well-being of affected communities. The commission's findings are particularly relevant as global conflicts continue to escalate, leading to increased numbers of displaced individuals. According to recent data, millions are currently living in precarious conditions, lacking basic healthcare access. This situation not only affects physical health but also has profound psychological impacts on individuals and communities. The report advocates for a coordinated international response to address these challenges, stressing the importance of integrating health services into humanitarian efforts. Healthcare professionals, policymakers, and humanitarian organizations are urged to prioritize health in crisis settings, ensuring that displaced populations receive the necessary support. The commission's recommendations aim to foster resilience in health systems and improve health outcomes for those affected by conflict and displacement. As the world grapples with ongoing crises, the insights from this commission serve as a crucial call to action for the global health community.

The Lancet · May 19

Innovative Approaches to Enhance Tuberculosis Case Detection

Recent advancements in technology are being leveraged to improve tuberculosis (TB) case detection, a critical step in managing and controlling this infectious disease. With TB remaining a significant public health challenge globally, innovative solutions are necessary to bridge the gap in diagnosis and treatment. The integration of spatial computing technologies, such as augmented reality (AR), virtual reality (VR), and extended reality (XR), is being explored to enhance the accuracy and efficiency of TB detection methods. Healthcare professionals and organizations are increasingly recognizing the potential of these technologies to transform traditional diagnostic processes. By utilizing neural rendering and digital twins, practitioners can create more immersive and interactive environments for training and patient engagement, ultimately leading to better outcomes in TB management. This approach not only aids in early detection but also helps in educating healthcare workers about the disease. The implications of improved TB case detection are profound, particularly in regions with high incidence rates. Enhanced diagnostic capabilities can lead to timely treatment, reducing transmission rates and improving public health outcomes. As countries continue to combat TB, the adoption of these innovative technologies could play a pivotal role in achieving global health targets. Moving forward, it is essential for healthcare stakeholders to collaborate on the development and implementation of these technologies. Continued research and investment in spatial computing applications for TB detection will be crucial in addressing the ongoing challenges posed by this disease.

Nature Medicine · May 19

Insights on Autism Spectrum Disorder: Diagnosis, Prevalence, and Treatment Discussed

In a recent episode of the Healthy Dialogue podcast, JAMA Senior Editor Derek C. Angus, MD, MPH, engaged in a detailed discussion with experts Dost Öngür, MD, PhD, and Jeremy Veenstra-VanderWeele, MD, regarding autism spectrum disorder (ASD). The conversation highlighted the complexities surrounding the diagnosis of ASD, emphasizing the importance of early detection and intervention. The prevalence of autism has been rising, with recent estimates suggesting that approximately 1 in 44 children in the United States is diagnosed with the condition, underscoring the need for increased awareness and resources. The experts discussed various treatment modalities, including behavioral therapies and pharmacological options, which can significantly improve outcomes for individuals with ASD. They stressed the importance of a multidisciplinary approach to care, involving healthcare providers, educators, and families to create supportive environments for those affected. The dialogue also touched on the ongoing research aimed at understanding the neurobiological underpinnings of autism, which could lead to more effective treatments in the future. As the conversation concluded, the experts called for continued advocacy and education to reduce stigma and improve access to care for individuals with autism. This discussion is particularly relevant for healthcare professionals who work with children and families affected by ASD, as it provides valuable insights into current trends and best practices in diagnosis and treatment.

JAMA Network · May 19